How to buy CytoDyn (CYDY) shares in Australia
Learn how to easily invest in CytoDyn shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CytoDyn (CYDY) is a biotech firm developing antibodies to combat serious medical conditions, such as HIV and cancer. The company is focused on exploring whether the antibody drug Leronlimab can contribute to the development of an HIV cure. CytoDyn was incorporated in 2002 and is based in Vancouver, Washington USA.
How to buy shares in CytoDyn
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for CytoDyn. Find the share by name or ticker symbol: CYDY. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CytoDyn reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$1.35, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CytoDyn, depending on your broker.
- Check in on your investment. Congratulations, you own a part of CytoDyn. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
CytoDyn stock price (OTCQB:CYDY)Use our graph to track the performance of CYDY stocks over time.
CytoDyn shares at a glance
|52-week range||US$1.25 - US$7.4|
|50-day moving average||US$1.7262|
|200-day moving average||US$2.021|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-0.255|
Where to buy CytoDyn stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy CytoDyn stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying CytoDyn shares?Before you consider CytoDyn, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
CytoDyn price performance over time
|1 week (2021-10-15)||5.63%|
|1 month (2021-09-22)||-39.02%|
|3 months (2021-07-22)||-16.67%|
|6 months (2021-04-22)||-54.27%|
|1 year (2020-10-22)||-44.03%|
|2 years (2019-10-22)||376.19%|
|3 years (2018-10-22)||188.46%|
|5 years (2016-10-21)||127.27%|
Stocks similar to CytoDyn
|Gross profit TTM||US$0|
|Return on assets TTM||-57.11%|
|Return on equity TTM||0%|
|Market capitalisation||US$937.5 million|
TTM: trailing 12 months
CytoDyn share dividends
We're not expecting CytoDyn to pay a dividend over the next 12 months.
CytoDyn share price volatility
Over the last 12 months, CytoDyn's shares have ranged in value from as little as US$1.25 up to US$7.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.8159. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CytoDyn in the news
CytoDyn : to Hold Webcast and Live Q/A on October 26 - Form 8-K
CytoDyn : Announces Delaware Court Has Denied Activist Group's Motion to Prevent Annual Meeting from Taking Place
CytoDyn : to Hold Webcast and Live Q/A on October 26
Frequently asked questions
More guides on Finder
How to buy BITO ETF units | $43.28
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Why is the AMP share price looking up today?
Shares in the wealth management giant have been largely stable in the last 6 months.
How to invest in the Judo Capital Holdings IPO
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
How to invest in the Alloggio Group IPO
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
How to invest in the Larvotto Resources IPO
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
How to invest in the Vulcan Steel IPO
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
How to invest in the Artrya IPO
Everything we know about the Artrya IPO, plus information on how to buy in.
How to invest in the 8 Au IPO
Everything we know about the 8 Au IPO, plus information on how to buy in.
How to invest in the Radiopharm Theranostics IPO
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
What has prompted the rebound in the Kogan share price?
The online retailer’s shares have lost more than half their value in the last 12 months.
Ask an Expert